AGEN moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend. In 35 of 38 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AGEN as a result. In 69 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for AGEN turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 39 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
The 10-day moving average for AGEN crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
AGEN broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AGEN's RSI Indicator exited the oversold zone, 31 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where AGEN advanced for three days, in 215 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 80 of 94 cases where AGEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. AGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.452) is normal, around the industry mean (2.988). P/E Ratio (2.133) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (1.994) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Be on the lookout for a price bounce soon.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PALI's RSI Indicator exited the oversold zone, 33 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for PALI just turned positive on October 08, 2026. Looking at past instances where PALI's MACD turned positive, the stock continued to rise in 33 of 42 cases over the following month. The odds of a continued upward trend are 79%.
Following a +5.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where PALI advanced for three days, in 168 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
PALI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PALI as a result. In 90 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The 10-day moving average for PALI crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
The 50-day moving average for PALI moved below the 200-day moving average on October 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PALI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PALI entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.004) is normal, around the industry mean (2.988). P/E Ratio (2.154) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. PALI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PALI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
AGEN | PALI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 90 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 40 | 78 | |
P/E GROWTH RATING 1..100 | 18 | 96 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AGEN's Valuation (52) in the Biotechnology industry is in the same range as PALI (78) in the null industry. This means that AGEN’s stock grew similarly to PALI’s over the last 12 months.
AGEN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PALI (100) in the null industry. This means that AGEN’s stock grew similarly to PALI’s over the last 12 months.
PALI's SMR Rating (98) in the null industry is in the same range as AGEN (100) in the Biotechnology industry. This means that PALI’s stock grew similarly to AGEN’s over the last 12 months.
AGEN's Price Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for PALI (78) in the null industry. This means that AGEN’s stock grew somewhat faster than PALI’s over the last 12 months.
AGEN's P/E Growth Rating (18) in the Biotechnology industry is significantly better than the same rating for PALI (96) in the null industry. This means that AGEN’s stock grew significantly faster than PALI’s over the last 12 months.
| AGEN | PALI | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 82% | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 89% |
| Momentum ODDS (%) | 2 days ago 87% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 87% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Advances ODDS (%) | 3 days ago 85% | 8 days ago 84% |
| Declines ODDS (%) | 9 days ago 90% | 4 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | 7 days ago 79% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AGEN’s FA Score shows that 1 FA rating(s) are green while PALI’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AGEN’s TA Score shows that 4 TA indicator(s) are bullish while PALI’s TA Score has 5 bullish TA indicator(s).
AGEN (@Biotechnology) experienced а -1.54% price change this week, while PALI (@Biotechnology) price change was -5.41% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
AGEN is expected to report earnings on Nov 09, 2026.
PALI is expected to report earnings on Nov 09, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, PALI has been closely correlated with RNAC. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if PALI jumps, then RNAC could also see price increases.
| Ticker / NAME | Correlation To PALI | 1D Price Change % | ||
|---|---|---|---|---|
| PALI | 100% | -2.10% | ||
| RNAC - PALI | 81% Closely correlated | +0.39% | ||
| AGEN - PALI | 81% Closely correlated | -0.31% | ||
| NCNA - PALI | 81% Closely correlated | -2.94% | ||
| TAOX - PALI | 81% Closely correlated | +4.88% | ||
| NRXP - PALI | 74% Closely correlated | +0.38% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ACTS | 25.27 | 0.22 | +0.88% |
| FIS Tactical Equity ETF (ACTS) | |||
| ATMP | 35.52 | 0.23 | +0.65% |
| Barclays ETN+ Select MLP ETN (ATMP) | |||
| GDXJ | 108.52 | 0.68 | +0.63% |
| VanEck Junior Gold Miners ETF (GDXJ) | |||
| UPAR | 15.33 | 0.03 | +0.17% |
| UPAR Ultra Risk Parity ETF (UPAR) | |||
| ORCX | 15.88 | -0.52 | -3.17% |
| Defiance Daily Target 2X Long ORCL ETF (ORCX) | |||